Enanta Pharmaceuticals, Inc. (FRA:9EP)

Market Cap	298.87M +169.0%
Revenue (ttm)	60.03M +7.4%
Net Income	-53.76M
EPS	-2.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	9.70
Previous Close	9.85
Day's Range	9.20 - 10.30
52-Week Range	5.45 - 14.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 120
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9EP

Financial Performance

In fiscal year 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.

Financial numbers in USD